Franco Lori

Virostatics Srl is a privately held small pharmaceutical company based in Sassari, Italy. The Italian company is dedicated to discovering and developing novel compounds for the treatment of cancers and viral diseases. The company focuses on novel, selective, host cell kinase targeted inhibitors and inherently hindering the oncogene myc. The team and advisors combine scientific, business, legal, and technology expertise, spanning from translational science through preclinical and clinical drug development. Virostatics has developed a bioaerosol system to test nebulized drug treatments, inhalers, disinfectants, or devices for virucidal activity in a state-of-the-art biosafety level 3 facility. The company has developed a robust pipeline of proprietary compounds to distinguish themselves from the competition through their unique kinase selectivity, efficacy, and safety profiles. The company was founded by Franco Lori, who has been the CEO since incorporation.

Power of the Dream Ventures, Inc. engages in the acquisition and development of technology. It operates through the Biotecchnology and Software divisions. The firm specializes in environmental technologies, power generation and storage, software products and services, biotechnology, medical devices, and disruptive technologies. The company was founded by Viktor Rozsnyay on August 17, 2006 and is headquartered in Budapest, Hungary.

Virostatics Srl is a privately held small pharmaceutical company based in Sassari, Italy. The Italian company is dedicated to discovering and developing novel compounds for the treatment of cancers and viral diseases. The company focuses on novel, selective, host cell kinase targeted inhibitors and inherently hindering the oncogene myc. The team and advisors combine scientific, business, legal, and technology expertise, spanning from translational science through preclinical and clinical drug development. Virostatics has developed a bioaerosol system to test nebulized drug treatments, inhalers, disinfectants, or devices for virucidal activity in a state-of-the-art biosafety level 3 facility. The company has developed a robust pipeline of proprietary compounds to distinguish themselves from the competition through their unique kinase selectivity, efficacy, and safety profiles. The company was founded by Franco Lori, who has been the CEO since incorporation.